NVP-BHG712

SKU: orb1300847

Description

NVP-BHG712

Research Area

Cardiovascular Research, Signal Transduction

Key Properties

• CAS Number: 940310-85-0
• MW: 503.48
• Purity: 98.63%
• Formula: C₂₆H₂₀F₃N₇O
• SMILES: Cc1ccc(cc1Nc1nc(nc2n(C)ncc12)-c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F
• Target: Bcr-Abl,Raf,Ephrin Receptor,Src
• Solubility: DMSO:24.7 mg/mL (49.06 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (3.97 mM)

Bioactivity

• Target IC50:
  c-Src:1.266 μM|C-Raf:0.395 μM|EphB4:25 nM|c-ABL:1.667 μM
• In Vivo:
  NVP-BHG712 exhibits dose-dependent inhibition of RTK autophosphorylation in A375 melanoma cells stably transfected, with EC50 values of 25 nM for EphB4 and 4.2 μM for VEGFR2.
• In Vitro:
  In a vascularization model induced by growth factors, NVP-BHG712 (3 mg/kg, p.o) significantly inhibited tissue formation and vascularization stimulated by VEGF through the suppression of EphB4 forward signaling. Additionally, NVP-BHG712 (10 mg/kg, oral administration) effectively reversed the VEGF-enhanced tissue formation and angiogenesis. NVP-BHG712 (3 mg/kg, orally) exhibited a sustained exposure in mouse plasma as well as lung and liver tissues for up to 8 hours at approximately 10 μM concentration, thereby resulting in long-lasting inhibition of EphB4 kinase activity.

Storage & Handling

• Storage: store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

c-Abl, BHG 712, BHG712, BHG-712, BcrAbl, c-Raf, c-Src, NVP BHG712, NVP-BHG 712, NVPBHG712, NVP-BHG712, NVP-BHG-712, inhibit, EphB4, EphrinReceptor, Ephrin Receptor, Inhibitor

Compound Identifiers

PubChem CID

16747388